{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:44:47Z","timestamp":1790379887919,"version":"4.1.0"},"reference-count":113,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease with a high prevalence of cardiovascular disease (CVD), obesity, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome. Among them, CVD is the most common cause of morbidity and mortality in psoriasis patients. Since CVD is associated with considerable morbidity and mortality, primary care clinicians are increasingly committed to reducing the risk of CVD in patients with psoriasis. Biologics targeting TNF-\u03b1, IL-12\/23, and IL-17 are systemic therapies that can dramatically improve the condition of psoriasis. Recent studies have reported that these inflammatory cytokine signals may promote atherosclerosis, suggesting that biologics might be effective for improving psoriasis as well as reducing the risk of CVD. Here, we reviewed cardiovascular risk in psoriasis patients, the association between psoriatic inflammation and atherosclerosis, and the efficacy of biologics for reducing the risk of cardiovascular diseases.<\/jats:p>","DOI":"10.3390\/jcm12031162","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T01:53:54Z","timestamp":1675302834000},"page":"1162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Biologics for Reducing Cardiovascular Risk in Psoriasis Patients"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7598-2833","authenticated-orcid":false,"given":"Hitoshi","family":"Terui","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-9778","authenticated-orcid":false,"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of Myocardial Infarction in Patients with Psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jaad.2020.12.044","article-title":"Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study","volume":"84","author":"Teklu","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jdv.15159","article-title":"Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study","volume":"33","author":"Gari","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4103\/0378-6323.183638","article-title":"Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: A hospital-based cross-sectional study","volume":"82","author":"Khanna","year":"2016","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks","volume":"139","author":"Reich","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/ijd.13699","article-title":"Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction","volume":"56","author":"Lynch","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: A concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an Anti\u2013Interleukin-17\u2013Receptor Antibody for Psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: Results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jid.2018.09.021","article-title":"Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis","volume":"139","author":"Brand","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/STROKEAHA.114.006516","article-title":"Interleukin 23 levels are increased in carotid atherosclerosis: Possible role for the interleukin 23\/interleukin 17 axis","volume":"46","author":"Abbas","year":"2015","journal-title":"Stroke"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/CIRCRESAHA.116.304794","article-title":"Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: Promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling","volume":"116","author":"Subramanian","year":"2015","journal-title":"Circ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1161\/ATVBAHA.111.227629","article-title":"Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E\u2013Deficient Mice","volume":"31","author":"Madhur","year":"2011","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_28","first-page":"864","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 Promotes Angiotensin II\u2013Induced Hypertension and Vascular Dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/jid.2012.366","article-title":"Association of cardiovascular and metabolic disease genes with psoriasis","volume":"133","author":"Lu","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000433528","article-title":"Prevalence of obesity in patients with psoriasis: Results of the national study PsoHealth3","volume":"231","author":"Jacobi","year":"2015","journal-title":"Dermatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdermsci.2009.11.002","article-title":"Prevalence of metabolic syndrome in Japanese psoriasis patients","volume":"57","author":"Takahashi","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr. Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","article-title":"Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry","volume":"86","author":"Enos","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/1346-8138.16096","article-title":"Body mass index, HbA1c and serum C\u2013reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital-based retrospective case\u2014Control study","volume":"48","author":"Terui","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_37","first-page":"1207","article-title":"Plasma adiponectin and leptin levels in Japanese patients with psoriasis","volume":"159","author":"Takahashi","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bjd.12735","article-title":"Diet and physical exercise in psoriasis: A randomized controlled trial","volume":"170","author":"Naldi","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archdermatol.2009.48","article-title":"Psoriasis and the risk of diabetes and hypertension: A prospective study of US female nurses","volume":"145","author":"Qureshi","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Armstrong, A.W., Lin, S.W., Chambers, C.J., Sockolov, M.E., and Chin, D.L. (2011). Psoriasis and hypertension severity: Results from a case-control study. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018227"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of psoriasis severity on hypertension control: A population-based study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PTT.S159163","article-title":"Type 2 diabetes and psoriasis: Links and risks","volume":"9","author":"Holm","year":"2019","journal-title":"Psoriasis Targets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","article-title":"Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7243\/2050-0866-3-3","article-title":"Psoriasis and insulin resistance: A review","volume":"3","author":"Fitzgerald","year":"2014","journal-title":"J. Diabetes Res. Clin. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/bjd.12101","article-title":"The association between psoriasis and dyslipidaemia: A systematic review","volume":"168","author":"Ma","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1468-3083.2007.02260.x","article-title":"The lipid profile in psoriasis: A controlled study","volume":"21","author":"Akhyani","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Shih, C.-M., Chen, C.-C., Chu, C.-K., Wang, K.-H., Huang, C.-Y., and Lee, A.-W. (2020). The roles of lipoprotein in psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030859"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diabetes.51.10.2929","article-title":"Tumor necrosis factor-\u03b1 stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP","volume":"51","author":"Zhang","year":"2002","journal-title":"Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The Risk of Stroke in Patients with Psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: A possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/joim.13311","article-title":"Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: A multi-centre cohort study","volume":"290","author":"Tinggaard","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jjcc.2018.10.008","article-title":"Risk of myocardial infarction in patients with psoriasis: A cross-sectional patient-population study in a Japanese hospital","volume":"73","author":"Shiba","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1346-8138.15052","article-title":"Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15-year nationwide population-based cohort study","volume":"46","author":"Jung","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2340\/00015555-2657","article-title":"Risk of Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis: A Nationwide Cohort Study","volume":"97","author":"Egeberg","year":"2017","journal-title":"Acta Derm.-Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1203475415602842","article-title":"Psoriasis as an independent risk factor for cardiovascular disease: An epidemiologic analysis using a national database","volume":"20","author":"Lai","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_58","first-page":"112","article-title":"Psoriasis and ischemic coronary artery disease","volume":"106","year":"2015","journal-title":"Actas Dermo Sifiliogr\u00e1ficas"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/jid.2015.8","article-title":"Psoriasis and Cardiometabolic Traits: Modest Association but Distinct Genetic Architectures","volume":"135","author":"Koch","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/09546634.2014.952609","article-title":"Risk of myocardial infarction in psoriasis patients: A retrospective cohort study","volume":"26","author":"Wu","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.114.009990","article-title":"Chronic Inflammatory Disorders and Risk of Type 2 Diabetes Mellitus, Coronary Heart Disease, and Stroke: A population-based cohort study","volume":"130","author":"Dregan","year":"2014","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/jid.2013.131","article-title":"Psoriasis Is Not Associated with Atherosclerosis and Incident Cardiovascular Events: The Rotterdam Study","volume":"133","author":"Dowlatshahi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2310\/7750.2013.13052","article-title":"Risk of Myocardial Infarction in Canadian Patients with Psoriasis: A Retrospective Cohort Study","volume":"17","author":"Levesque","year":"2013","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: A population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1346-8138.2011.01401.x","article-title":"Psoriasis and increased risk of ischemic stroke in Taiwan: A nationwide study","volume":"39","author":"Chiang","year":"2012","journal-title":"J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.2011.10774.x","article-title":"Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: A cohort study","volume":"166","author":"Li","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2010.01.050","article-title":"Increased risk of acute myocardial infarction in patients with psoriasis: A 5-year population-based study in Taiwan","volume":"64","author":"Lin","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2133.2011.10494.x","article-title":"Medical comorbidity associated with psoriasis in adults: A population-based study","volume":"165","author":"Yang","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1468-3083.2009.03537.x","article-title":"Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample","volume":"24","author":"Schmitt","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/jid.2009.321","article-title":"Psoriasis May Not be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort","volume":"130","author":"Wakkee","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1365-2133.2008.09020.x","article-title":"Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: An inception cohort study with a nested case\u2014Control analysis","volume":"160","author":"Brauchli","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of Psoriasis with Coronary Artery, Cerebrovascular, and Peripheral Vascular Diseases and Mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1468-3083.2009.03318.x","article-title":"Prevalence of myocardial infarction in patients with psoriasis in central China","volume":"23","author":"Xiao","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis","volume":"159","author":"Kaye","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"829709","DOI":"10.3389\/fcvm.2022.829709","article-title":"Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study","volume":"9","author":"Liu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_80","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights from the PALM Registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamadermatol.2021.4467","article-title":"Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention among Persons with Psoriatic Disease","volume":"158","author":"Barbieri","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/jamadermatol.2021.4723","article-title":"Psoriasis and Cardiovascular Disease\u2014An Ounce of Prevention Is Worth a Pound of Cure","volume":"158","author":"Garshick","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","article-title":"Inflammation and Atherosclerosis: The End of a Controversy","volume":"136","author":"Hansson","year":"2017","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, Atherosclerosis, and Coronary Artery Disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF01606532","article-title":"Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis","volume":"423","author":"Kishikawa","year":"1993","journal-title":"Virchows Arch."},{"key":"ref_89","first-page":"1721","article-title":"Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques","volume":"142","author":"Tipping","year":"1993","journal-title":"Am. J. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/1744666X.2016.1195686","article-title":"Immune-mediated mechanisms of atherosclerosis and implications for the clinic","volume":"12","author":"Nus","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.116.301313","article-title":"Inflammation and Immunity in Diseases of the Arterial Tree","volume":"116","author":"Libby","year":"2015","journal-title":"Circ. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/eurheartj\/ehs399","article-title":"Interleukin-17 in atherosclerosis and cardiovascular disease: The good, the bad, and the unknown: Players and layers","volume":"34","author":"Liuzzo","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jid.2021.07.190","article-title":"A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation","volume":"142","author":"Garshick","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","article-title":"Association of Biologic Therapy with Coronary Inflammation in Patients with Psoriasis as Assessed by Perivascular Fat Attenuation Index","volume":"4","author":"Elnabawi","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaad.2013.06.019","article-title":"Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study","volume":"69","author":"Szakonyi","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/jdv.14841","article-title":"Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis","volume":"32","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ced.14180","article-title":"Effect of biologics targeting interleukin-23\/-17 axis on subclinical atherosclerosis: Results of a pilot study","volume":"45","author":"Marovt","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Piros, \u00c9.\u00c1., Szab\u00f3, \u00c1., Rencz, F., Brodszky, V., Szalai, K., Galajda, N., Szilveszter, B., D\u00f3sa, E., Merkely, B., and Holl\u00f3, P. (2021). Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients. Life, 11.","DOI":"10.3390\/life11090919"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ajd.12044","article-title":"Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis","volume":"54","author":"Tan","year":"2013","journal-title":"Australas. J. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","article-title":"Anti\u2013tumour necrosis factor-\u03b1 therapy increases body weight in patients with chronic plaque psoriasis: A retrospective cohort study","volume":"22","author":"Gisondi","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_104","first-page":"235","article-title":"Effects of tumor necrosis factor \u03b1 inhibitors extend beyond psoriasis: Insulin sensitivity in psoriasis patients with type 2 diabetes mellitus","volume":"97","author":"Shabaan","year":"2016","journal-title":"Cutis"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-05759-2","article-title":"Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: A systematic review and meta-analysis","volume":"7","author":"Ursini","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09546634.2016.1254145","article-title":"The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: A retrospective study","volume":"29","author":"Shaaban","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00395-010-0135-y","article-title":"Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability","volume":"106","author":"Erbel","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.immuni.2018.09.011","article-title":"An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis","volume":"49","author":"Fatkhullina","year":"2018","journal-title":"Immunity"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e008257","DOI":"10.1161\/JAHA.117.008257","article-title":"IL-23R Deficiency Does Not Impact Atherosclerotic Plaque Development in Mice","volume":"7","author":"Engelbertsen","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:21:37Z","timestamp":1760120497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":113,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12031162"],"URL":"https:\/\/doi.org\/10.3390\/jcm12031162","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}